Steven L. Hoerter is President and CEO of Deciphera Pharmaceuticals. Prior to joining Deciphera, Mr. Hoerter was Chief Commercial Officer at Agios Pharmaceuticals, Inc. where he built and led the team responsible for the commercialization of the company’s portfolio of first-in-class medicines for oncology and rare genetic diseases. Prior to joining Agios in 2016, Mr. Hoerter was Executive Vice President and Chief Commercial Officer at Clovis Oncology, Inc. Before joining Clovis, Mr. Hoerter was General Manager and Management Center Head at Roche for the Sub-Saharan Africa and Indian Ocean Region. From 2005 to 2010, he held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s BioOncology business. Prior to that, Mr. Hoerter held commercial roles at Chiron Corporation and Eli Lilly and Company in the U.S., Europe, and Africa. Mr. Hoerter currently serves on the Board of Directors at Constellation Pharmaceuticals, a biotechnology focused on developing novel therapeutics for patients with cancers associated with abnormal gene expression and was previously a member of the Board of Directors of Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, until the company’s acquisition by Roche in 2017. Mr. Hoerter received his B.A. from Bucknell University, M.B.A. from Tilburg University in the Netherlands and M.S. in management from Purdue University.
Daniel L. Flynn, Ph.D. is CSO and Founder of Deciphera Pharmaceuticals. Before founding Deciphera in 2003, Dr. Flynn held senior roles in small molecule chemistry with various biotechnology and pharmaceuticals companies, including as Senior Director of Chemistry with Millennium Pharmaceuticals, Director, Medicinal Chemistry at Amgen Inc., and Director of Medicinal Chemistry, Combinatorial Chemistry and Research Fellow at Monsanto Company, G.D. Searle Unit. Dr. Flynn is currently Adjunct Professor of Medicinal Chemistry at the University of Kansas-Lawrence and has served as the national Chair for the Division of Medicinal Chemistry of the American Chemical Society. Dr. Flynn received both his Ph.D. in medicinal chemistry and his B.S. in pharmacy from the University of Kansas, and he completed post-doctorate training in synthetic organic chemistry at Indiana University.
Caroline Chevalier is Vice President of Human Resources at Deciphera Pharmaceuticals. Ms. Chevalier has more than 15 years of human resources experience within the pharmaceutical and biotechnology industry and joined the Deciphera team in 2018 to build and lead the HR Operations function. Prior to joining Deciphera, she served as Senior Director, Total Rewards & HR Operations at TESARO where she was responsible for developing and implementing scalable policies and programs to attract and retain talent in a high growth, global organization. Ms. Chevalier also held several roles of increasing responsibility at Cubist Pharmaceuticals where she was for over 12 years and gained experience across all aspects of HR, supporting the organization through commercialization, global expansion and multiple acquisitions. Ms. Chevalier holds a B.A. in Economics from Boston College.
Margarida Duarte is Senior Vice President, Head of International at Deciphera Pharmaceuticals. Ms. Duarte joined Deciphera in 2021 and has over 15 years of experience in the global pharmaceutical industry and previous leadership roles in commercial, marketing, and strategy, along with experience leading cross functional teams in medical, regulatory, supply chain, and global product development. Prior to joining Deciphera, she served as Vice President, Head of Commercial Canada, Europe, and Middle East and Africa for Alnylam Pharmaceuticals where she led the company’s commercial growth and expansion in her regions, including the launch of Alnylam’s first products in rare genetic diseases. Before joining Alnylam, Ms. Duarte held multiple commercial and marketing leadership positions at STEPSTONE Pharma, Exelixis, Onyx Pharmaceuticals, and Amgen, with a focus in oncology and hematology. Ms. Duarte received a Master’s degree in Pharmacy from Universidade de Lisboa and an Executive Master’s degree in Marketing Management from Instituto Universitário de Lisboa (ISCTE).
Eric Haltom is Senior Vice President, Clinical Operations at Deciphera Pharmaceuticals. Mr. Haltom joined Deciphera in June 2016 and has over 28 years of industry experience from both academic institutions and industry. He has successfully built and led clinical operations teams supporting Phase 1 to Phase 3 drug development programs and registries at both emerging biotechnology and established pharmaceutical companies. He has contributed to drug development programs intended to provide new therapeutic options to patients with cancer, cardiovascular, CNS and rare disease indications. Mr. Haltom received his B.A. degree in Business from Saint Anselm College.
Jeff Held is Senior Vice President, General Counsel of Deciphera Pharmaceuticals. Prior to joining Deciphera, Mr. Held was General Counsel at another public biotechnology company. Mr. Held has also served in senior legal positions, and built the legal function, at several Boston-based life science and technology companies. Mr. Held spent the first part of his career at law firms in New York and Boston as a corporate lawyer specializing in counseling high-growth companies. Mr. Held earned a JD from Fordham University School of Law and a BA, cum laude, from Tufts University.
Tucker Kelly is Chief Financial Officer of Deciphera Pharmaceuticals. Prior to joining Deciphera, Mr. Kelly served as Chief Financial Officer of AdvanDx, Inc., a private molecular diagnostics company, from 2012 to 2014. Prior to joining AdvanDx, Mr. Kelly served as chief financial officer for various public and private life science companies, including deCODE genetics, Inc. from 2010 to 2011 and Critical Therapeutics, Inc. from 2007 to 2008. Prior to joining Critical Therapeutics, Mr. Kelly was a life sciences investment banker at Robertson Stephens and Canaccord Adams and was an attorney in the corporate and securities group of Foley, Hoag and Elliot, LLP. Mr. Kelly holds a Juris Doctor with honors degree from the University of Chicago Law School and a Bachelor of Science in Foreign Services degree cum laude from the Georgetown University School of Foreign Service.
Daniel C. Martin is Chief Commercial Officer at Deciphera Pharmaceuticals. Mr. Martin has more than 20 years of commercial experience within the biopharmaceutical industry with extensive background in oncology, including immuno-oncology. Prior to joining Deciphera, he served as Senior Vice President, Commercial at Heron Therapeutics where he built the company’s commercial organization, including establishing marketing, sales, and market access functions, and launched its oncology portfolio. Mr. Martin also served as commercial lead for Heron’s portfolio strategy and new product planning across all therapeutic areas. Before joining Heron, Mr. Martin held commercial leadership positions at Dendreon and at Amgen, where he played lead roles in multiple U.S. and global oncology launches. Earlier in his career, Mr. Martin was a management consultant with Deloitte Consulting where he advised global biopharmaceutical companies in commercial strategy and operations. Mr. Martin received his undergraduate degree with honors in economics and biology from the University of Virginia and an MBA from the Wharton School at the University of Pennsylvania.
Jama Pitman is Senior Vice President, Regulatory and Quality Assurance at Deciphera Pharmaceuticals. Ms. Pitman joined Deciphera in January 2015 and has over 18 years of industry experience. She has successfully led regulatory teams in supporting Phase 1 to Phase 3 drug development programs at both emerging biotechnology and established pharmaceutical companies. She has contributed to drug development programs intended to provide new therapeutic options to patients with cancer, including, multiple myeloma, prostate cancer, thyroid cancer, and ovarian cancer. Additionally, she has been a key contributor to the development of drugs to treat patients with non-oncology diseases such as Hepatitis B and C, Hereditary Angioedema, Fabry Disease, Hunter’s Syndrome, and Gaucher’s Disease. Ms. Pitman received her B.S. degree in Microbiology from the University of New Hampshire.
Stephen B. Ruddy, Ph.D. is Chief Technical Officer of Deciphera Pharmaceuticals. Dr. Ruddy has more than 25 years of global pharmaceutical management and leadership experience in small-molecule and biologics development and manufacturing. Prior to joining Deciphera, he served as Vice President of Pharmaceutical Development at TESARO, Inc., an oncology-focused biopharmaceutical company, where he built and led a CMC organization that enabled multiple small-molecule NDA and MAA approvals and advanced multiple biologic immuno-oncology product candidates from discovery into clinical development. Before joining TESARO, Dr. Ruddy served as Senior Director, Technology Development & Operations at ViroPharma Inc., which was later acquired by Shire plc. Prior to joining ViroPharma, he served in CMC leadership roles of increasing responsibility at Elan Corporation plc, Merck & Co., Inc., NanoSystems LLC and Sterling Winthrop Pharmaceuticals. Dr. Ruddy earned a B.S. in Pharmacy and a Ph.D. in Pharmaceutics, both from the University of North Carolina at Chapel Hill.
Matthew L. Sherman, M.D. is Executive Vice President and Chief Medical Officer of Deciphera Pharmaceuticals. Dr. Sherman brings over 25 years of experience as a physician-scientist in clinical drug development in oncology and hematology at leading biotechnology and pharmaceutical companies. From 2006 to 2018, Dr. Sherman served as Chief Medical Officer of Acceleron Pharma, Inc., where he led medical research, clinical operations, biostatistics, data management, clinical pharmacology, medical writing, outsourcing and pharmacovigilance. Before joining Acceleron, Dr. Sherman was Senior Vice President and Chief Medical Officer at Synta Pharmaceuticals (now Madrigal Pharmaceuticals). Prior to Synta, Dr. Sherman spent over a decade at Wyeth-Ayerst Research/Genetics Institute, where he led the successful submission, positive Oncologic Drug Advisory Committee recommendation, and FDA approval for the first antibody immune-drug conjugate for acute myeloid leukemia. He has published 260 original papers, book chapters, reviews and abstracts, and is listed as an inventor on 13 patents. He currently serves as a director of Pieris Pharmaceuticals. He also serves on the Geisel School of Medicine at Dartmouth Board of Advisors and Alumni Council. Dr. Sherman received a S.B. in Chemistry from the Massachusetts Institute of Technology and a M.D. from Dartmouth Medical School. He completed his internal medicine residency at Georgetown University Medical Center and fellowship in Medical Oncology at the Dana-Farber Cancer Institute. Dr. Sherman is board certified in Internal Medicine and Medical Oncology and has held various academic and teaching positions at Harvard Medical School with corresponding clinical appointments at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston.
Rodrigo Ruiz Soto, MD/MSc has served as Vice President of Clinical Development and Translational Medicine since May 2017. Dr. Ruiz Soto is an experienced Clinical Development Hematologist-Oncologist with more than 15 years of experience in Clinical Research. Prior to Deciphera, Dr. Ruiz Soto was Senior Medical Director at ImmunoGen where he played a key role advancing antibody-drug conjugates from early to late stage development. Prior to ImmunoGen, Dr. Ruiz Soto served as Medical Director at Sanofi and before that at GSK working in various oncology indications from Phase 1 to Phase 3, including small molecules and biologics.
Dr. Ruiz Soto holds a MD degree from the Universidad Nacional Autonoma de Mexico. He completed his internal medicine residency and fellowship in hematology at the National Institute of Medical Sciences and Nutrition Salvador Zubiran in Mexico. Dr. Ruiz Soto trained in medical oncology at the Institut de Cancerologie Gustave Roussy in France and earned a Master of Science in Oncology from the Paris XI University-Institut Gustave Roussy.